Safety signal dampens reception for mipomersen antisense.
Kling
Jim
J
D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D009841:Oligonucleotides / Q000009:adverse effects* / Q000627:therapeutic use*; D014481:United States
D000924:Anticholesteremic Agents; D009841:Oligonucleotides; C524142:mipomersen